Skip to main content

Advertisement

SpringerLink
Log in

Chronomodulated chemotherapy versus conventional chemotherapy for advanced colorectal cancer: a meta-analysis of five randomized controlled trials

  • Original Article
  • Published:
International Journal of Colorectal Disease Aims and scope Submit manuscript

Abstract

Purpose

The purpose of this study was to systematically compare the efficacy and safety of chronomodulated chemotherapy with conventional chemotherapy in patients with advanced colorectal cancer.

Method

Eligible studies were identified from electronic databases (Medline, Embase, and the Cochrane Library). The efficacy data included overall survival (OS) and objective response rate (ORR), and toxicities data contained diarrhea, vomiting and nausea, mucositis, asthenia, and peripheral sensory neuropathy. The meta-analysis was performed with the fixed-effect model or random-effect model according to heterogeneity.

Result

From 79 articles screened, five randomized controlled trials (RCTs) met the inclusion criteria contributing a total of 958 participants. There was a significant OS benefit (hazard ratio (HR) = 0.82; 95% confidence interval (CI) 0.69 to 0.97; P = 0.023) in favor of the chronomodulated chemotherapy. The ORR was not significantly different between two arms (relative risk = 1.27; 95% CI 0.88 to 1.83; P = 0.196). A higher incidence of grade 3/4 mucositis (odds ratio = 2.26, 95% CI 1.34 to 3.83; P = 0.724), asthenia (2.15, 1.30 to 3.56; P = 0.428), and a lower incidence of grade 3/4 neutropenia (0.26, 0.16 to 0.42; P = 0.641) were associated with the chronomodulated chemotherapy. The two arms were similar in terms of grade 3/4 diarrhea (1.10, 0.72 to 1.69; P = 0.756), vomiting and nausea (0.69, 0.42 to1.13; P = 0.239), and peripheral sensory neuropathy (0.56, 0.25 to 1.27, 0.164).

Conclusion

Chronomodulated chemotherapy showed significant improvement in OS comparing with conventional chemotherapy. Side effects of the chronomodulated chemotherapy are predictable and manageable. But these results still need more high-quality RCTs for confirmation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Ferlay J, Bray F, Pisani P et al (2004) GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. IARC CancerBase no. 5, version 2.0. IARC, Lyon

    Google Scholar 

  2. Jemal A, Siegel R, Ward E et al (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71–96

    Article  PubMed  Google Scholar 

  3. Schmoll HJ, Büchele T, Grothey et al (1999) Where do we stand with 5-FU? Semin Oncol 26:589–605

    CAS  PubMed  Google Scholar 

  4. Von Roemeling R, Hrushesky WJ (1989) Circadian patterning of continuous floxuridine infusion reduces toxicity and allows higher dose intensity in patients with widespread cancer. J Clin Oncol 7:1710–1719

    Google Scholar 

  5. Daher GC, Zhang RW, Soong SJ et al (1991) Circadian variation of fluoropyrimidine catabolic enzymes in rat liver: possible relevance to 5-fluorodeoxyuridine chemotherapy. Drug Metab Dispos Biol Fate Chem 19:285–287

    CAS  PubMed  Google Scholar 

  6. Harris BE, Song R, Soong SJ et al (1989) Circadian variation of 5-fluorouracil catabolism in isolated perfused rat liver. Cancer Res 49:6610–6614

    CAS  PubMed  Google Scholar 

  7. Diasio R, Zhang R, Lu Z et al (1992) Circadian variation of fluoropyrimidine metabolic enzymes: importance to fluorodeoxyuridine (FdURD) chemotherapy. In Proceedings of the 5th International Conference on Chronopharmacology, Amelia Island, Fla; abstr IV-1

  8. El Kouni M, Naquib F (1992) Circadian rhythm of hepatic pyrimidine metabolizing enzymes and plasma uridine concentration in mice. In Proceedings of the 5th International Conference on Chronopharmacology, Amelia Island, Fla; abstr IV-2

  9. Zhang R, Lu E, Liu T et al (1992) Circadian rhythm of rat spleen cytoplasmic thymidine kinase: possible relevance to 5-fluorodeoxyuridine chemotherapy. In Proceedings of the 5th International Conference on Chronopharmacology, Amelia Island, Fla; abstr IV-3

  10. Malmary-Nebot M, Labat C, Casanovas A et al (1985) Aspect chronobiologique de l'action du mdthrotrexate sur la dihydrofolate re'ductase. Ann Pharm Fr 43:337–343

    CAS  PubMed  Google Scholar 

  11. Levi FA, Zidani R, Vannetzel JM et al (1994) Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J Natl Cancer Inst 86:1608–1617

    Article  CAS  PubMed  Google Scholar 

  12. Mahesh K, Parmar B, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statist Med 17:2815–2834

    Article  Google Scholar 

  13. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1–12

    Article  CAS  PubMed  Google Scholar 

  14. Kjaergard LL, Villumsen J, Gluud C (2001) Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med 135:982–989

    CAS  PubMed  Google Scholar 

  15. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M et al (1998) Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 352:609–613

    Article  CAS  PubMed  Google Scholar 

  16. Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F (2000) Methods for meta-analysis in medical research. Wiley, Chichester

    Google Scholar 

  17. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088–1101

    Article  CAS  PubMed  Google Scholar 

  18. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634

    CAS  PubMed  Google Scholar 

  19. Garufi C, Vanni B, Aschelter AM, Zappalà AR, Bria E, Nisticò C, Sperduti I, Cognetti F, Terzoli E (2006) Randomised phase II study of standard versus chronomodulated CPT-11 plus chronomodulated 5-fluorouracil and folinic acid in advanced colorectal cancer patients. Eur J Cancer 42:608–616

    Article  CAS  PubMed  Google Scholar 

  20. Levi F, Zidani R, Misset JL (1997) Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy. Lancet 350:681–686

    Article  CAS  PubMed  Google Scholar 

  21. Giacchetti S, Bjarnason G, Garufi C et al (2006) Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group. J Clin Oncol 24:3562–3569

    Article  CAS  PubMed  Google Scholar 

  22. Ramanathan RK, Bjarnason GA, Bernard SA, Desimone P, Braich T, Evars JP, Hrushesky WJ, Jolivet J (2008) A four-arm, randomized, multicenter phase II trial of oxaliplatin combined with varying schedules of 5-fluorouracil as first-line therapy in previously untreated advanced colorectal cancer. Clin Colorectal Cancer 7(2):134–139

    Article  CAS  PubMed  Google Scholar 

  23. Blumenthal RD, Waskewich C, Goldenberg DM et al (2001) Chronotherapy and chronotoxicity of the cyclooxygenase-2 inhibitor, celecoxib, in athymic mice bearing human breast cancer xenografts. Clin Cancer Res 7:3178–3185

    CAS  PubMed  Google Scholar 

  24. Lévi F (2002) From circadian rhythms to cancer chronotherapeutics. Chronobiol Int 19:1–19

    Article  PubMed  Google Scholar 

  25. Hrushesky WJ (1985) Circadian timing of cancer chemotherapy. Science 228:73–75

    Article  CAS  PubMed  Google Scholar 

  26. Lévi F, Benavides M, Chevelle C et al (1990) Chemotherapy of advanced ovarian cancer with 4′-0-tetrahydropyranyl doxorubicin and cisplatin: a randomized phase II trial with an evaluation of circadian timing and doseintensity. J Clin Oncol 8:705–714

    PubMed  Google Scholar 

  27. Mormont MC, Waterhouse J, Bleuzen P et al (2000) Marked 24-h rest–activity rhythms are associated with better quality of life, better response and longer survival in patients with metastatic colorectal cancer and good performance status. Clin Cancer Res 6:3038–3045

    CAS  PubMed  Google Scholar 

  28. Sephton SE, Sapolsky RM, Kraemer HC et al (2000) Diurnal cortisol rhythm as a predictor of breast cancer survival. J Natl Cancer Inst 92:994–1000

    Article  CAS  PubMed  Google Scholar 

  29. Smaaland R, Laerum OD, Sothern RB et al (1992) Colony-forming units-granulocyte-macrophage and DNA synthesis of human bone marrow are circadian stage-dependent and show covariation. Blood 79:2281–2287

    CAS  PubMed  Google Scholar 

  30. Levi F, Schibler U (2007) Circadian rhythms: mechanisms and therapeutic implications. Annu Rev Pharmacol Toxicol 47:593–628

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Coloproctological Surgery, First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, Guangxi Zhuang Autonomous Region, People’s Republic of China

    Cun Liao, Jing Li, Qiong Bin, Yunfei Cao & Feng Gao

Authors
  1. Cun Liao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jing Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Qiong Bin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yunfei Cao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Feng Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Yunfei Cao or Feng Gao.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Liao, C., Li, J., Bin, Q. et al. Chronomodulated chemotherapy versus conventional chemotherapy for advanced colorectal cancer: a meta-analysis of five randomized controlled trials. Int J Colorectal Dis 25, 343–350 (2010). https://doi.org/10.1007/s00384-009-0838-4

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00384-009-0838-4

Keywords

Search

Navigation